New ruthenium tach complexes as water-soluble chemotherapy agents

Ruthenium complexes are currently attracting much attention in the field of medicinal chemistry as they provide numerous properties which make them an appropriate candidate for drug design. Recently, a series of ruthenium tach complexes with extremely high in vitro activity and high solubility have...

Full description

Bibliographic Details
Main Author: Arkawazi, Sham
Other Authors: Lynam, Jason ; Walton, Paul
Published: University of York 2017
Subjects:
540
Online Access:https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.731573
id ndltd-bl.uk-oai-ethos.bl.uk-731573
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-7315732019-03-05T15:29:19ZNew ruthenium tach complexes as water-soluble chemotherapy agentsArkawazi, ShamLynam, Jason ; Walton, Paul2017Ruthenium complexes are currently attracting much attention in the field of medicinal chemistry as they provide numerous properties which make them an appropriate candidate for drug design. Recently, a series of ruthenium tach complexes with extremely high in vitro activity and high solubility have been developed. Cis-1,3,5-triaminocyclohexane (tach) provides a hydrogen bond donor through amine groups, which aids both solubility and interaction with biomolecules. The chemistry of the ruthenium tach complexes was developed in order to understand their activity in a biological environment. The parent compound, tach [2] was modified by the incorporation of a new functional group (benzyl) into the coordination sphere of the ligand and synthesis a new tach analogue, tachmb [3]. The coordination chemistry of [3] was performed with a range of different ruthenium precursors to yield [Ru(tachmb)(DMSO)Cl2] [5], [Ru(tachmb)(PPh3)Cl2] [7], and [Ru(tachmb)(dppb)Cl]Cl [9]. The anti-proliferative activity of the modified tach [3] and the complexes were evaluated with in vitro tests against A549 (human lung cancer) and A2780 (human ovarian cancer) cell lines. The activity of [3] showed mild activity in comparison to the non-toxic tach, [2]. Both complexes [7] and [9] showed high activity; in particular, the activity of [9] was found to exceed that of cisplatin in both cell lines. Two new analogues of ruthenium tach complexes tagged with fluorescent ligands were synthesised and fully characterised, [Ru(tach)(FL-I)Cl]Cl [10] and [Ru(tach)(FL-II)Cl]Cl [13]. Two previously reported complexes were also prepared; one complex with high cytotoxic activity ([Ru(tach)(dppp)Cl]Cl, [11]) and one complex with light sensitive behaviour ([Ru(tach)(phen)(DMSO)], [12]). The interactions of these complexes with Calf Thymus DNA (CT-DNA) and bovine serum albumin (BSA) were examined spectrophotometrically. The results show intercalation behaviour of [10] and [12] towards DNA while complex [11] instead exhibits high binding affinity towards BSA. The cytotoxicity of the complexes indicates that proteins may be the potential biological targets of ruthenium tach anti-cancer drugs.540University of Yorkhttps://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.731573http://etheses.whiterose.ac.uk/18881/Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 540
spellingShingle 540
Arkawazi, Sham
New ruthenium tach complexes as water-soluble chemotherapy agents
description Ruthenium complexes are currently attracting much attention in the field of medicinal chemistry as they provide numerous properties which make them an appropriate candidate for drug design. Recently, a series of ruthenium tach complexes with extremely high in vitro activity and high solubility have been developed. Cis-1,3,5-triaminocyclohexane (tach) provides a hydrogen bond donor through amine groups, which aids both solubility and interaction with biomolecules. The chemistry of the ruthenium tach complexes was developed in order to understand their activity in a biological environment. The parent compound, tach [2] was modified by the incorporation of a new functional group (benzyl) into the coordination sphere of the ligand and synthesis a new tach analogue, tachmb [3]. The coordination chemistry of [3] was performed with a range of different ruthenium precursors to yield [Ru(tachmb)(DMSO)Cl2] [5], [Ru(tachmb)(PPh3)Cl2] [7], and [Ru(tachmb)(dppb)Cl]Cl [9]. The anti-proliferative activity of the modified tach [3] and the complexes were evaluated with in vitro tests against A549 (human lung cancer) and A2780 (human ovarian cancer) cell lines. The activity of [3] showed mild activity in comparison to the non-toxic tach, [2]. Both complexes [7] and [9] showed high activity; in particular, the activity of [9] was found to exceed that of cisplatin in both cell lines. Two new analogues of ruthenium tach complexes tagged with fluorescent ligands were synthesised and fully characterised, [Ru(tach)(FL-I)Cl]Cl [10] and [Ru(tach)(FL-II)Cl]Cl [13]. Two previously reported complexes were also prepared; one complex with high cytotoxic activity ([Ru(tach)(dppp)Cl]Cl, [11]) and one complex with light sensitive behaviour ([Ru(tach)(phen)(DMSO)], [12]). The interactions of these complexes with Calf Thymus DNA (CT-DNA) and bovine serum albumin (BSA) were examined spectrophotometrically. The results show intercalation behaviour of [10] and [12] towards DNA while complex [11] instead exhibits high binding affinity towards BSA. The cytotoxicity of the complexes indicates that proteins may be the potential biological targets of ruthenium tach anti-cancer drugs.
author2 Lynam, Jason ; Walton, Paul
author_facet Lynam, Jason ; Walton, Paul
Arkawazi, Sham
author Arkawazi, Sham
author_sort Arkawazi, Sham
title New ruthenium tach complexes as water-soluble chemotherapy agents
title_short New ruthenium tach complexes as water-soluble chemotherapy agents
title_full New ruthenium tach complexes as water-soluble chemotherapy agents
title_fullStr New ruthenium tach complexes as water-soluble chemotherapy agents
title_full_unstemmed New ruthenium tach complexes as water-soluble chemotherapy agents
title_sort new ruthenium tach complexes as water-soluble chemotherapy agents
publisher University of York
publishDate 2017
url https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.731573
work_keys_str_mv AT arkawazisham newrutheniumtachcomplexesaswatersolublechemotherapyagents
_version_ 1718993481360211968